Eliquis Nipping At The Heels of NOAC Market Leader Xarelto

–But the overall market for the new oral anticoagulants continues to expand. The new oral anticoagulant (NOAC) market is growing larger and is becoming increasingly competitive. The latest market data shows that apixaban (Eliquis, Pfizer and BristolMyers Squibb) is challenging the established leader in the field, rivaroxaban (Xarelto, Johnson & Johnson). According to recent data...Click here to continue reading...
Source: CardioBrief - Category: Cardiology Authors: Tags: People, Places & Events Policy & Ethics apixaban Eliquis NOAC oral anticoagulants rivaroxaban Xarelto Source Type: blogs
More News: Cardiology